Immunosuppressive Effects of Myeloid Cells on Chimeric Antigen Receptor T Cells within the Glioblastoma Neuronal Microenvironment - Report - DentalSpire

Immunosuppressive Effects of Myeloid Cells on Chimeric Antigen Receptor T Cells within the Glioblastoma Neuronal Microenvironment

  • By

  • Junyi Zhang

  • Jasmin von Ehr

  • Thomas Look

  • Jasim Kada Benotmane

  • Nicolas Neidert

  • Jan Kueckelhaus

  • Tobias Weiss

  • Dieter Henrik Heiland

  • Yahaya A. Yabo

  • March 13, 2026

  • 0 min

Share

Clinical Report: Immunosuppressive Effects of Myeloid Cells on CAR-T Cells in GB

Overview

This study investigates the immunosuppressive effects of myeloid cells on CAR-T cells within the glioblastoma microenvironment. It highlights the role of tumor-associated macrophages in promoting T cell dysfunction and identifies key transcriptional regulators affecting CAR-T cell efficacy.

Background

Chimeric antigen receptor (CAR)-T cell therapy has shown success in hematologic malignancies but struggles with solid tumors like glioblastoma (GB). The immunosuppressive tumor microenvironment and T cell exhaustion present significant barriers to effective CAR-T therapy in GB. Understanding these interactions is crucial for improving therapeutic strategies against this aggressive cancer.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

['CAR-T cells initially exhibit antitumor effects in the glioblastoma microenvironment but subsequently lose efficacy.', 'CD163-positive myeloid cells contribute to T cell dysfunction and promote an immunosuppressive environment.', 'Interactions between myeloid cells and T cells drive transcriptional shifts towards T cell exhaustion.', 'MAF and BACH2 are identified as key transcriptional regulators of CAR-T cell function.', 'The study utilized a novel human neocortical slice model to better mimic the human glioblastoma microenvironment.']

Clinical Implications

The findings underscore the need for strategies to counteract myeloid cell-mediated immunosuppression in glioblastoma patients receiving CAR-T therapy. Targeting the interactions between myeloid cells and T cells may enhance the efficacy of CAR-T treatments in this challenging tumor type.

Conclusion

This research provides critical insights into the mechanisms of T cell dysfunction in glioblastoma, highlighting the importance of addressing the tumor microenvironment to improve CAR-T cell therapy outcomes.

References

  1. Author(s)/Org, Source, Year -- Immune Modulation in Glioma Cases
  2. Author(s)/Org, Source, Year -- Radiotherapy induces an immediate inflammatory reaction in malignant glioma: a clinical microdialysis study
  3. Author(s)/Org, Source, Year -- Immune System Engagement in Glioblastoma CAR T Cell Therapy: The Role of Cytokines, Myeloid Cells, and Chemokine Networks
  4. Author(s)/Org, Source, Year -- Modification of T Cells to Target CS1 Improves Eradication of Myeloma Cells
  5. Author(s)/Org, Source, Year -- Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma
  6. Author(s)/Org, Source, Year -- A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
  7. Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma | The Oncologist | Oxford Academic
  8. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma - PubMed
  9. IL-12-secreting CAR-T cells reprogram the tumor microenvironment and improve efficacy against heterogeneous models of glioblastoma | Journal for ImmunoTherapy of Cancer

Original Source(s)

Immunosuppressive Effects of Myeloid Cells on Chimeric Antigen Receptor T Cells within the Glioblastoma Neuronal Microenvironment

  • by Junyi Zhang, Jasmin von Ehr, Thomas Look, Jasim Kada Benotmane, Nicolas Neidert, Jan Kueckelhaus, Tobias Weiss, Dieter Henrik Heiland, Yahaya A. Yabo

  • March 13, 2026

Related Content

Paediatric traumatic brain injury: unique population and unique challenges

Spatial transcriptomics uncovers TAC-OGEs heterogeneity and FN1/MMP9 signature in ameloblastoma

Defibrotide for prophylaxis of sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) in pediatric high-risk patients: consensus guidelines from the European Society for Blood and Marrow Transplantation (EBMT)